Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Travera Inc
Seagen Inc.
KaliVir Immunotherapeutics
iOnctura
Sotio Biotech Inc.
Ohio State University
Endeavor Biomedicines, Inc.
University of Nebraska